|
Video: What is a Stock Split?
|
|
SpringWorks Therapeutics a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing medicines for underserved patient populations suffering from devastating rare diseases and cancer. Co.'s product candidate, nirogacestat, is an oral, small molecule gamma secretase inhibitor in development as a monotherapy for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. Co.'s second product candidate is mirdametinib, an oral, small molecule MEK inhibitor initially in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas. According to our SpringWorks Therapeutics stock split history records, SpringWorks Therapeutics has had 0 splits. | |
|
SpringWorks Therapeutics (SWTX) has 0 splits in our SpringWorks Therapeutics stock split history database.
Looking at the SpringWorks Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into SpringWorks Therapeutics shares, starting with a $10,000 purchase of SWTX, presented on a split-history-adjusted basis factoring in the complete SpringWorks Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
09/16/2019 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$23.73 |
|
End price/share: |
$45.53 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
91.87% |
|
Average Annual Total Return: |
15.17% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$19,186.75 |
|
Years: |
4.61 |
|
|
|
|
|